Drug hypersensitivity in HIVElizabeth Phillips
Centre for Pharmacology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
Curr Opin Allergy Clin Immunol 7:324-30. 2007
..This review focuses on the current knowledge of the epidemiology, pathophysiology and clinical features of drug hypersensitivity reactions of drugs used in the management of the HIV-infected patient...
- HLA and drug-induced toxicity
Elizabeth J Phillips
Royal Perth Hospital and PathWest, Department of Clinical Immunology and Immunogenetics, Western Australia, Australia
Curr Opin Mol Ther 11:231-42. 2009
....
HLA and pharmacogenetics of drug hypersensitivityRebecca Pavlos
The Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia
Pharmacogenomics 13:1285-306. 2012
..The ultimate translation of the knowledge of how drugs interact with HLA would be applicable to preclinical drug screening programs to improve the safety and cost-effectiveness of drug design and development...
Drug hypersensitivity: pharmacogenetics and clinical syndromesElizabeth J Phillips
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
J Allergy Clin Immunol 127:S60-6. 2011
..International collaborative consortia have been formed with the goal of developing phenotypic standardization and undertaking HLA and genome-wide analyses in diverse populations with these syndromes...
- Pharmacogenetics of drug hypersensitivity
Elizabeth J Phillips
Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Australia
Pharmacogenomics 11:973-87. 2010
..HLA-B*5701 screening to prevent abacavir hypersensitivity syndrome is an example of a test now in widespread routine clinical use in the developed world...
- Successful translation of pharmacogenetics into the clinic: the abacavir example
Elizabeth Phillips
Institute for Immunology and Infectious Diseases, Murdoch University and Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Western Australia, Australia
Mol Diagn Ther 13:1-9. 2009
..The abacavir 'example' can be applied to other drugs to facilitate the development and operationalization of genetic tests that may be useful to predict and prevent otherwise unpredictable drug reactions...
- HLA-B*5701 screening for hypersensitivity to abacavir
Simon Mallal
Royal Perth Hospital and Murdoch University, Perth, Australia
N Engl J Med 358:568-79. 2008
..This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir...
- Pharmacogenetics and the potential for the individualization of antiretroviral therapy
Elizabeth J Phillips
Centre for Clinical Pharmacology and Infectious Diseases, Royal Perth Hospital, Murdoch University, Perth, Australia
Curr Opin Infect Dis 21:16-24. 2008
....
- External quality assessment of HLA-B*5701 reporting: an international multicentre survey
Emma Hammond
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
Antivir Ther 12:1027-32. 2007
..We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR...
- Cytokine profiling in abacavir hypersensitivity patients
Coral Ann M Almeida
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Australia
Antivir Ther 13:281-8. 2008
..We have analysed the cytokine profile in antigen-presenting cells and the T-lymphocytes that are involved in the pathological immune response to abacavir...
- A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome
Annalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
Pharmacogenet Genomics 16:353-7. 2006
..Following risk stratification with this assay, it would be anticipated that identification of HLA-B*5701 using molecular HLA typing methods would be required in <10% of the screened population...
- Immune responses to abacavir in antigen-presenting cells from hypersensitive patients
Annalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
AIDS 21:1233-44. 2007
..HLA-B*5701 and Hsp70 493T alleles have been shown to predict susceptibility to this hypersensitivity...
- Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity
Annalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
Pharmacogenomics 5:643-55. 2004
..g., major histocompatibility complex alleles associated with abacavir hypersensitivity). The current and potential clinical utility of pharmacogenetic testing in HIV management will also be emphasized...
- Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant
Annalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Second Floor, North Block, Royal Perth Hospital, Perth 6000, Australia
Proc Natl Acad Sci U S A 101:4180-5. 2004
..These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir...
- Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
Annalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
AIDS 19:97-9. 2005
..These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens...
